Loipl Johann, Schmekal Bernhard, Biesenbach Georg
Second Department of Medicine, Section Nephrology, General Hospital, Linz, Austria.
Ren Fail. 2005;27(3):305-8.
There are only a few data in the literature concerning metabolic control in insulin-treated diabetic patients with end stage renal disease (ESRD). The aim of the study was to find out the long-term impact of hemodialysis on glycemic control and lipid values in type 2 diabetic patients. Twenty insulin-treated type 2 diabetic patients (age 62 +/- 9 years, f:m=6:14) were evaluated. We compared HbAlc, fasting blood glucose (FBG), body weight, serum lipids, insulin requirement, and blood-pressure (BP) 12 and 6 months before dialysis, at the start of dialysis, and 6 as well as 12 months after the start.
The mean HbA1c- and FBG-values were not significantly different before and after the start of dialysis therapy. The average insulin requirement was 26 +/- 10 IU/day in the predialysis period, 25 +/- 12 IU/day at the start, and 24 +/- 13 as well as 22 +/- 13 IU/day after the start of dialysis. The mean cholesterol level fell significantly from 199 +/- 63 and 190 +/- 49 mg/dL in the predialysis phase to 167 +/- 62 and 157 +/- 38 mg/dL after dialysis began. The triglyceride concentrations decreased only slightly after the start of dialysis. The incidence of hypoglycemia (n/patient/month) was markedly lower in the predialysis phase (0.4 vs. 0.6, NS) than after start of dialysis. In patients with residual diuresis (<500 mL urine/day) the needed insulin doses decreased significantly by 29% compared to patients with higher residual diuresis, whose insulin requirement remained unchanged. In summary, hemodialysis had no significant long-term effect on glycemic control in insulin-treated type 2 diabetic patients, but incidence of hypoglycemia tended to be higher under hemodialysis than in the predialysis period. Lipid levels tended to be lower after the initiation of dialysis therapy. Insulin requirement under hemodialysis decreased only in patients with loss of residual urine volume (below 500 mL urine/day).
文献中关于胰岛素治疗的终末期肾病(ESRD)糖尿病患者代谢控制的数据很少。本研究的目的是探讨血液透析对2型糖尿病患者血糖控制和血脂水平的长期影响。对20例接受胰岛素治疗的2型糖尿病患者(年龄62±9岁,女∶男 = 6∶14)进行了评估。我们比较了透析前12个月和6个月、透析开始时、透析开始后6个月以及12个月时的糖化血红蛋白(HbAlc)、空腹血糖(FBG)、体重、血脂、胰岛素需求量和血压(BP)。
透析治疗开始前后,平均HbA1c值和FBG值无显著差异。透析前期平均胰岛素需求量为26±10 IU/天,开始透析时为25±12 IU/天,透析开始后6个月和12个月分别为24±13 IU/天和22±13 IU/天。平均胆固醇水平从透析前期的199±63和190±49 mg/dL显著降至透析开始后的167±62和157±38 mg/dL。透析开始后甘油三酯浓度仅略有下降。透析前期低血糖发生率(每患者每月次数)明显低于透析开始后(0.4对0.6,无显著性差异)。与残余尿量较高且胰岛素需求量不变的患者相比,残余尿量<500 mL/天的患者所需胰岛素剂量显著降低29%。总之,血液透析对胰岛素治疗的2型糖尿病患者的血糖控制没有显著的长期影响,但透析期间低血糖发生率往往高于透析前期。透析治疗开始后血脂水平趋于降低。血液透析期间,仅残余尿量减少(低于500 mL/天)的患者胰岛素需求量下降。